International uniform response criteria for multiple myeloma.
B G M Durie, J-L Harousseau, J S Miguel...
https://pubmed.ncbi.nlm.nih.gov/16855634/Actively Recruiting
Led by Dr. Zaineb Akram · Updated on 2026-07-08
10
Participants Needed
2
Research Sites
N/A
Total Duration
Multiple myeloma is a cancer of plasma cells characterized by the production of abnormal monoclonal immunoglobulin proteins and displacement of normal bone marrow cells. This disease causes bone damage, anemia, infections, high calcium levels, kidney problems, and neurological issues. Despite advances in treatments like proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplants, multiple myeloma remains incurable and often relapses, highlighting the need for new therapies. This study is a phase 2 trial investigating a novel CAR-T cell therapy targeting BCMA in adults with relapsed or refractory multiple myeloma. The study involves collecting the patients own T cells, genetically modifying them to recognize BCMA on myeloma cells, then infusing these CAR-T cells back into the patient. This autologous BCMA-directed CAR-T cell therapy is given after screening and eligibility confirmation. The treatment aims to attack the cancer cells by enhancing the immune response. The trial is being conducted in Pakistan and focuses on patients who have had at least three prior treatment lines or are double refractory to key therapies. Participants will be screened for eligibility, provide informed consent, and undergo assessments including lab tests and disease measurements before treatment. After infusion, safety, tolerability, manufacturing feasibility, and delivery of the CAR-T product will be closely monitored for up to one year. The study also involves regular follow-ups and evaluations to assess participant health, organ function, and disease status throughout the trial period, which spans from enrollment to one year post-treatment.
CONDITIONS
CAR-T in Relapsed/Refractory Multiple Myeloma
N
Nadia Sial, Ph.D
M
Maryam Khan, MBBS, MRCP(UK), FCPS (Cl Haem)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Dr. Zaineb Akram
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 28 days
Participants are screened for eligibility, provide informed consent, and undergo necessary assessments within 28 days before starting treatment.
1 visit (in-person)
Duration - Single infusion followed by monitoring
Participants receive autologous BCMA-directed CAR-T cell therapy after their T cells are collected, modified, and expanded in the lab.
Multiple visits for treatment administration and monitoring
Duration - Up to 12 months
Participants are monitored for safety, tolerability, and treatment effects for up to one year after CAR-T infusion.
Regular follow-up visits for assessments and evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
B G M Durie, J-L Harousseau, J S Miguel...
https://pubmed.ncbi.nlm.nih.gov/16855634/Cesar Sommer, Bijan Boldajipour, Tracy C Kuo...
https://pubmed.ncbi.nlm.nih.gov/31005597/Janine M Buonato, Justin P Edwards, Liubov Zaritskaya...
https://pubmed.ncbi.nlm.nih.gov/35737298/Danielle T Avery, Susan L Kalled, Julia I Ellyard...
https://pubmed.ncbi.nlm.nih.gov/12865416/B G M Durie, J F S Miguel, J Blade...
https://pubmed.ncbi.nlm.nih.gov/26487274/Dr. Zaineb Akram
Lead Sponsor